CD8A and neoplasm: Preclinical study in mice. 747 exhibited good efficacy of tumour growth suppression in an orthotopic liver tumour model. Effect was mediated by significant reduction in TAMs and expansion of CD8+ T cells. 747 also potentiated the anti-tumour effects of sorafenib in the same model.